2011
DOI: 10.1016/j.atherosclerosis.2010.12.031
|View full text |Cite
|
Sign up to set email alerts
|

Long-term treatment with low-dose metoprolol CR/XL is associated with increased plaque echogenicity: The Beta-blocker Cholesterol-lowering Asymptomatic Plaque Study (BCAPS)

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

1
9
0

Year Published

2013
2013
2023
2023

Publication Types

Select...
6
2
1

Relationship

1
8

Authors

Journals

citations
Cited by 21 publications
(10 citation statements)
references
References 30 publications
1
9
0
Order By: Relevance
“…However, GSM values differ also in studies including similar populations. The same large differences in GSM values could be found in two studies on patients with asymptomatic plaques (Lind & Lind, 2011;Ostling et al, 2011). In the other two studies, Adobe Photoshop â was used, however, with different values for standardization of the grey scale.…”
Section: Discussionsupporting
confidence: 52%
“…However, GSM values differ also in studies including similar populations. The same large differences in GSM values could be found in two studies on patients with asymptomatic plaques (Lind & Lind, 2011;Ostling et al, 2011). In the other two studies, Adobe Photoshop â was used, however, with different values for standardization of the grey scale.…”
Section: Discussionsupporting
confidence: 52%
“…The risk of rupture of an atherosclerotic plaque is not only dependent on the plaque size but on the composition of the plaque. 17 Vulnerable plaque is typically characterized by a thin fibrous cap and increased accumulation of lipids and inflammatory cells. 17 This plaque morphology can be assessed as gray scale median (GSM).…”
Section: Outcome Measuresmentioning
confidence: 99%
“…17 Vulnerable plaque is typically characterized by a thin fibrous cap and increased accumulation of lipids and inflammatory cells. 17 This plaque morphology can be assessed as gray scale median (GSM). Thus, we also explored the effects of long-term intensive lipid-lowering therapy on GSM.…”
Section: Outcome Measuresmentioning
confidence: 99%
“…This raises the possibility that IM-GSM might be amenable to beneficial modification (increased IM-GSM) by controlling BMI and related CV risk factors. A 3-year treatment with a β-blocker showed a significant increase in plaque echogenicity (Ostling et al 2011). A post-hoc analysis of the METEOR study has also suggested a beneficial effect of 2-year rosuvastatin treatment on IM-GSM in individuals with low IM-GSM at baseline .…”
Section: Discussionmentioning
confidence: 95%